Welcome to our dedicated page for Aligos Therapeutics SEC filings (Ticker: ALGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aligos Therapeutics SEC filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing therapies for liver and viral diseases. Its Form 8-K reports furnish results of operations, business progress updates, clinical and regulatory events for pevifoscorvir sodium, and material agreements such as the exclusive license for development and commercialization in Greater China.
Proxy materials cover annual meeting procedures, stockholder voting matters, board governance, and compensation-related disclosures. Other current reports document executive officer appointments, compensatory arrangements, exhibit filings, and the company’s common stock listed on the Nasdaq Capital Market under ALGS.
Aligos Therapeutics director Heather Preston received a new stock option grant. The award covers 5,860 shares of common stock with an exercise price of $5.50 per share and expires on June 25, 2036.
The option will vest and become exercisable in full on the earlier of the first anniversary of the June 25, 2026 grant date or immediately prior to the company’s 2027 annual stockholder meeting, provided she continues serving the company through that date.
Aligos Therapeutics director Margarita Chavez received a grant of stock options covering 5,860 shares of common stock. The options have an exercise price of $5.50 per share and expire on June 25, 2036.
According to the grant terms, all 5,860 options will vest and become exercisable as to 100% of the underlying shares on the earlier of the first anniversary of the June 25, 2026 grant date or immediately prior to Aligos Therapeutics' 2027 annual stockholder meeting, provided she continues to serve the company through that vesting date.
Aligos Therapeutics director Bridget A. Martell received a grant of 5,860 stock options to buy common shares at an exercise price of $5.50 per share. The options vest 100% on the earlier of the first anniversary of the grant date or immediately before the company’s 2027 annual stockholder meeting, contingent on continued service.
Aligos Therapeutics director James Paul Scopa received a new stock option grant covering 5,860 shares of common stock. The options have an exercise price of $5.50 per share and expire on June 25, 2036.
The grant vests and becomes fully exercisable as to 100% of the 5,860 shares on the earlier of the first anniversary of the grant date or immediately prior to Aligos Therapeutics' 2027 annual stockholder meeting, provided Scopa continues serving the company through that vesting date. This is a compensation-related award, not an open-market stock purchase or sale.
Aligos Therapeutics director Carole Nuechterlein received a new stock option grant. She was awarded options to purchase 5,860 shares of Aligos Therapeutics common stock at an exercise price of $5.50 per share. Following this grant, she holds options for 5,860 underlying shares.
According to the award terms, the options will vest and become exercisable for 100% of the 5,860 shares on the earlier of the first anniversary of the grant date or immediately prior to the company’s 2027 annual stockholder meeting, subject to her continuous service through the vesting date. The options are scheduled to expire on June 25, 2036.
Aligos Therapeutics director Peter Hirth received a stock option grant for 5,860 shares of common stock at an exercise price of $5.50 per share. The option vests in full on the earlier of the first anniversary of the grant date or immediately before the 2027 annual stockholder meeting, assuming continuous service, and expires in 2036.
Aligos Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders and an amendment to its 2020 Employee Stock Purchase Plan (ESPP). Stockholders approved adding 500,000 shares for issuance under the Amended ESPP and removing its automatic “evergreen” annual share increase feature, fixing the total share reserve.
Two Class III directors, Bridget Martell and Carole Nuechterlein, were elected to serve until the 2029 annual meeting. Stockholders ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026. They also approved, on an advisory basis, the compensation of named executive officers and chose to hold future advisory “say-on-pay” votes every year. The record date for the meeting covered 5,388,223 shares of voting common stock outstanding.
Aligos Therapeutics, Inc.’s Chair, President and CEO, Lawrence M. Blatt, has filed a Schedule 13D reporting beneficial ownership of 316,228 shares of common stock, or about 5.6% of voting shares outstanding. This is based on 5,388,223 voting shares as of May 1, 2026.
His stake includes directly held shares, multiple trusts and an IRA, 12,206 shares issuable under exercisable warrants, and 215,606 shares underlying stock options exercisable within 60 days of June 16, 2026. Blatt states he may buy more, sell, or pursue strategic actions in his capacity as CEO and director, including possible transactions affecting Aligos’s capital structure, assets, or governance.
Aligos Therapeutics reports a Schedule 13G filing disclosing beneficial ownership by Lawrence M. Blatt. The filing states the Reporting Person beneficially owns 286,213 shares of Common Stock, representing 5.1% of the class, based on 5,388,223 shares outstanding as of May 1, 2026.
The ownership mix includes directly held shares, trusts, an IRA, 12,206 shares underlying exercisable warrants, and 185,591 shares underlying stock options exercisable or exercisable within 60 days of March 31, 2026.
Aligos Therapeutics, Inc. ownership update: Woodline Partners LP reports beneficial ownership of 239,362 shares of Voting Common Stock, representing 4.4% of the class based on 5,387,807 shares outstanding as of March 2, 2026. The count includes 62,000 shares issuable upon exercise of warrants.
The filing clarifies sole voting and dispositive power over the reported shares and is presented by Woodline as investment adviser to Woodline Master Fund LP. The statement is an ownership disclosure amendment and does not itself effect any transaction.